Eighty-four non-pregnant women with a history of previous severe preeclampsia, Hemolysis, elevated liver function, low platelets (HELLP) syndrome, intrauterine growth restriction, placental abruption, fetal loss and recurrent miscarriage were included. In 27 (31%) women, thrombophilia was diagnosed by routine testing; in this group, 15 women also had abnormal thromboelastometry. In 57 women, no thrombophilia was found; in this group, 32 women had an abnormal thromboelastometry.
Preeclampsia and cardiovascular disease share many risk factors, and women with preeclampsia are at increased risk of cardiovascular mortality later in life. We investigated whether risk factors associated with cardiovascular disease and preeclampsia remain elevated months postpartum.
Methods
WemeasuredplasmasolubleFMSliketyrosinekinase1(sFlt1),endoglin, placental growth factor (PlGF), cellular fibronectin (cFN), uric acid, homocysteine and asymmetric dimethylarginine (ADMA) in 30 women with uncomplicated normotensive pregnancies compared with 20 women with preeclampsia in samples collected at predelivery and again several months postpartum (average 10.6 + 6.2 months). Data were mean + SD or median (interquartile range). Statistical analysis was by Wilcoxon rank-sum or Student's unpaired t-tests with statistical significance accepted at P , 0.05.
Results
The mean concentrations of sFlt1, endoglin, PlGF, homocysteine, ADMA, cFN and uric acid was all significantly different in samples collected predelivery in subjects with preeclampsia compared with controls (P , 0.05). ADMA (0.67 + 0.17 versus 0.53 + 0.09 mM), cFN (43.8 + 26.1 versus 30.3 + 17.1 mg/mL) and uric acid (5.3 + 0.8 versus 4.5 + 1.2 mg/dL) remained significantly higher postpartum in subjects with previous preeclampsia compared with postpartum controls (respectively).
Conclusion
Biological markers associated with altered vascular function or cardiovascular risk are elevated in women with preeclampsia and some remain significantly higher in postpartum preeclamptic women. These data suggest that vascular dysfunction persists in women with previous preeclampsia and may contribute to the increased risk of future cardiovascular disease. Risk factors for cardiovascular disease 10 years after preeclampsia 
Objectives
To determine the prevalence of risk factors for cardiovascular disease in women with preeclampsia (PE).
Methods
Forty women with PE and 14 normotensive pregnant women treated 10 or more years before at Hospital de Clínicas de Porto Alegre were submitted to clinical and laboratorial exams.
Results
Patients with PE for 10 or more years had significantly higher diastolic blood pressure (P ¼ 0.047), body mass index (BMI) (P ¼ 0.019) and abdominal circumference (P ¼ 0.026) than the control group. The group of patients with PE presented positive correlations between BMI and diastolic blood pressure (BP [0.341, P ¼ 0.031]) and systolic BP (0.407, P ¼ 0.009).
Conclusion
Patients with PE for 10 or more years presented significantly higher diastolic BP, BMI and abdominal circumference measurements than those in the control group. This emphasizes the importance of long-term follow-up assessment for cardiovascular risk factors in patients with previous PE.
Angiotensin receptor agonistic autoantibodies from preeclamptic patients pass through placenta and affect the fetal development
Preeclampsia is frequently associated with increased rate of intrauterine growth restriction (IUGR). We have recently shown that key features of preeclampsia, including hypertension, proteinuria and placental abnormalities, and small fetuses appeared in pregnant mice following injection with either total IgG or affinity-purified angiotensin receptor agonist autoantibodies (AT1-AA) from women with preeclampsia. However, whether these antibodies can cross placenta and have a detrimental effect on fetal development is unknown. To address this issue, we first test whether AT1-AA exist in human cord blood of preeclamptic patients. Using Western blot analysis and 4XNFAT luciferase bioassay, we found that AT1-AA exist in both maternal and fetal circulation of preeclamptic patients. Realizing that the autoantibody enters the fetal circulation, it is possible that these antibodies have detrimental consequences on fetal development, resulting from the activation of AT1 receptors in the fetus and neonate. To test this hypothesis, we propose to use our antibody-induced mouse model of preeclampsia. Briefly, purified total IgG or affinity-purified AT1-AA were injected into day 13 pregnant mice with or without losartan, AT1 receptor specific blocker or 7-amino acid peptide that correspond to a site on the second extracellular loop of the AT1 receptor. Blood pressure and urinary protein levels were monitored to ensure that the pregnant mice injected with AT1-AA or total IgG resulting in key preeclamptic features: hypertension and proteinuria. Once we confirmed the mice injected with total IgG or AT1-AA showed hypertension and proteinuria, mice were sacrificed, fetal blood and multiple organs were collected for enzyme-linked immunosorbent assay (ELISA) and histological studies. The antibodies were detectable in fetal mice circulation by Western blot and ELISA after injection to pregnant mice five days later. In addition to the small fetus, we found that multiple fetal organ growth was retarded, including liver and kidney. The IUGR mediated by AT1-AA was partially inhibited by either losartan or 7-aa epitope peptide, supporting the detrimental effect via the autoantibodies specifically bound to AT1 receptor.
Taken together, we conclude that AT1-AA from preeclamptic patients can cross the placenta leading to IUGR by the activation of AT1 receptor.
Short-term maternal cardiovascular outcomes after preeclampsia: what is the real risk?
Sindhu Srinivas MD MSCE, Andrea Edlow MD and Michal Elovitz MD University of Pennsylvania, Philadelphia, USA Objectives Cardiovascular disease is the leading cause of death in women. Women with a history of preeclampsia appear to be at increased risk for long-term cardiovascular morbidity and mortality. This study assessed whether a pregnancy complicated by pre-eclampsia is associated with an increased prevalence of maternal cardiovascular risk factors shortly after delivery.
Study design
Seventy-nine cases and 140 controls enrolled in a prospective case-control study were evaluated in this planned follow-up analysis. The presence of hypertension and a composite outcome of cardiovascular risk (hypertension, diabetes, dyslipidaemia) were assessed by phone interview 6-13 months after delivery using a standardized questionnaire. Chi-square and multivariable logistic regression analyses were performed comparing cases and preterm cases (delivery ¼ 34 weeks) to controls.
Results
Cases were more likely than controls to have hypertension (adjusted odds ratio [AOR] ¼ 10.7 [4.3-26.9], P , 0.001) and cardiovascular risk (AOR 5.4 [2.6-10.9], P , 0.001) after adjusting for confounders. Women with preterm preeclampsia had higher odds of hypertension .75], P , 0.001) and cardiovascular risk , P , 0.001) compared with controls. After excluding cases with history of hypertension prior to pregnancy, an increased risk for hypertension .2], P , 0.001) and cardiovascular risk (AOR ¼ 6.6 [3-14.4], P , 0.001) persisted among cases compared with controls.
Discussion
Pregnancy complications, such as preeclampsia, may provide a window for intervention and prevention by identifying women at risk for cardiovascular morbidity years prior to disease onset. This study, and recent reports of long-term cardiovascular mortality after preeclampsia, mandate further research to determine the mechanism of this increased risk in order to improve the overall cardiovascular health of women.
Preeclampsia and long-term maternal mortality
Rolv Skjaerven PhD
University of Bergen, Bergen, Norway
Women who experience a preterm birth in a preeclamptic pregnancy have been shown to have excess mortality, especially due to cardiovascular causes. Also, it has repeatedly been shown that women who deliver a low-birth-weight infants may be at excess risk for cardiovascular disease. These studies have focused on first births. We consider the more complete reproductive experience of the women, since restriction to only the first birth may disclose some of the important mechanisms for the observed excess mortality. We use data from the population-based Medical Birth Registry of Norway, covering the period 1967-2004 and comprising 2.2 million births. We identify all women with a first birth between 1967 and 1996, and follow them until death or 2004. We restrict to women who die in the age range 40-69 years, to focus deaths after reproduction.
There were more than 13,000 deaths among women with a first birth. Women who had preterm preeclampsia in the first pregnancy and no further births had five-fold increased total mortality compared with women with no preeclampsia and two or more births (High risk [HR] ¼ 4.8; 95% confidence interval 3.3-7.0). However, if a second birth followed the preeclamptic pregnancy, the risk was negligible (HR ¼ 1.11; 0.73-1.7). A weaker pattern was seen for women with term preeclampsia in first birth (HR ¼ 2.6; 2.1-3.4 and HR ¼ 1.04; 0.87-1.24, respectively). The excess mortality for women with only one pregnancy, without a preeclamptic condition is seen also for men, however for men there is no added effect of preeclampsia. The results remain after adjusting for period of birth, maternal age and maternal education. Deaths due to cardiovascular causes are more strongly related to preterm preeclampsia, but excluding cardiovascular deaths did not change the results.
Higher risk among women with no subsequent births may reflect the effects of maternal morbidity, which could decrease fertility or reduce the woman's interest in additional children.
Thus, parity may reflect the health of the woman as well as her desired family size. The underlying biological and social mechanisms that link pregnancy outcome, parity and long-term maternal health have not been described and deserve careful consideration in perinatal epidemiology. 
Background
Women who develop preeclampsia in pregnancy are at increased risk of coronary heart disease and stroke in later life. The offspring from pregnancies complicated by preeclampsia have higher blood pressures during childhood, but little is known about their longterm health. We hypothesized that preeclampsia would lead to an increased risk of cardiovascular disease in the offspring.
Methods
We studied 6410 subjects in the Helsinki Birth Cohort, who were born as singletons in Helsinki, Finland, during 1934-44. We used the mothers' blood pressure levels and the presence of proteinuria, recorded at antenatal clinic visits and at birth hospital, to define preeclampsia (severe and not severe) and hypertension without proteinuria with blood pressure cutpoints of the National High Blood Pressure Education Programme (NHBPEP) 2000 criteria. Hazard ratios were calculated using Cox regression, adjusting for birth weight, gestational age and sex. Diagnoses for coronary heart disease and stroke came from national hospital discharge and death registers with data available for linkage from 1971 onwards.
Results
Two hundred and eighty-four (4.4%) of the pregnancies were complicated by preeclampsia (164 of which with severe disease) and 1592 (24.8%) fulfilled the criteria for hypertension without proteinuria. Of the offspring, 464 (7.2%) had a diagnosis of coronary heart disease and 272 (4.2%) had stroke. The hazard ratio for coronary heart disease among the offspring whose mothers had preeclampsia was 1.2 (95% confidence interval 0.8-1.8; P ¼ 0.4); for stroke it was 1.7 (1.0-2.7; P ¼ 0.03). The risk of stroke was confined to offspring of mothers with severe preeclampsia (1.9; 1.0-3.6; P ¼ 0.05). Maternal hypertension without proteinuria was not associated with coronary heart disease (1.0; 0.8-1.3; P ¼ 0.7), but it did predict stroke (hazard ratio 1.3; 1.0-1.8; P ¼ 0.04) in the offspring.
Conclusion
People born after pregnancies complicated by preeclampsia or hypertension without proteinuria are at increased risk of stroke. We found no evidence foran increased risk of coronary heart disease. 
Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review and meta-analyses

Objectives
To determine if women with preeclampsia/eclampsia (PET) are at increased risk of long-term cardiovascular sequelae.
Study methods
We included case-control and cohort studies that examined the development of cardiovascular disease or mortality more than six weeks postpartum in women with and without PET, and that controlled for confounding variables. Two reviewers independently assessed titles, abstracts, articles, quality and extracted data. A random effects model was used to pool data.
Results
Five case-control and 10 cohort studies met eligibility criteria with 118,990 preeclamptic and 2,259,576 non-preeclamptic women. Most studies reported on relatively young women, with 11 focusing on women ,56 years of age.
Relative to women with uncomplicated pregnancies, women with a history of PET had an increased risk of subsequent cardiac disease in both the case-control studies (odds ratio 2.47, 95% confidence interval 1.22-5.01) and the cohort studies (RR 2.33, 1.95-2.78), as well as an increased risk of cerebrovascular disease (RR 2.03, 1.54-2.67), peripheral arterial disease (RR 1.87, 0.94 -3.73) and cardiovascular mortality (Relative Risk [RR] 2.29, 1.73-3.04).
Meta-regression revealed a graded relationship between the severity of preeclampsia and the risk of cardiac disease, with mild, moderate and severe PET having RRs of 2.00 (1.83-2.19), 2.99 (2.51-3.58), 5.36 (3.96-7.27 for cardiac disease), P ,0.0001.
Conclusion
Relative to women with uncomplicated pregnancies, women with a history of PET had approximately double the risk of early cardiac, cerebrovascular or peripheral arterial disease, as well as cardiovascular mortality. Further research is needed to determine the mechanisms underlying this association and what interventions might prevent these serious complications.
Predictors of maternal blood pressure 21 years postdelivery: a birth cohort study Leonie Callaway FRACP PhD Ã , H David McIntyre FRACP Ã , Abdullah Mamun PhD Ã , Jake Najman PhD Ã , Gail Williams PhD Ã and Debbie Lawlor † Ã University of Queensland, Brisbane, Australia; † University of Bristol,
Bristol, UK
Objectives
To assess the role of hypertensive disorders of pregnancy in predicting future hypertension compared with currently recognized risk factors for hypertension, such as body mass index, alcohol intake, smoking status and physical activity.
Design and setting
The Australian Birth Cohort Study -the Mater University of Queensland Study of Pregnancy, a prospective study of women who received antenatal care at a major public hospital in south Brisbane between 1981 and 1983.
Participants
A total of 2114 women who were followed for 21 years after the index pregnancy and who attended a clinical visit for the assessment of blood pressure. 
Results
Of 2114 women followed, at the 21-year assessment, 27.48% had elevated blood pressure and 16.27% were hypertensive. Of the 191 women who had hypertensive disorders of pregnancy, 17.80% had undertreated hypertension, 35.60% had untreated elevated blood pressure, 15.18% had adequately treated hypertension and 31.94% did not have hypertension. In addition to hypertensive disorders of pregnancy, factors that were associated with maternal hypertension 21 years after the index pregnancy were maternal age, gestational weight gain, general health status at the 21-year follow-up, alcohol consumption, change in body mass index from prepregnancy to 21 years postdelivery and self-reported diabetes status at 21-year follow-up.
Conclusion
Hypertensive disorders of pregnancy are an important independent predictor of future hypertension. Women with hypertensive disorders of pregnancy are an identifiable group who are at risk of future overt cardiovascular disease, and in this study, more than half of these women do not have adequately identified or treated hypertension. 
Aim
To compare maternal and perinatals results in two similar periods.
Material and Methods
From 1973 to 2008 a total of 54 pregnancies of 22 or more weeks of gestation were managed in 47 women delivering a total of 57 newborns. Although the obstetrical, neonatal and nephrologic teams have been the same along these years, the medical systems and techniques have changed, and we have divided our cases into two periods: 1 from 1973 to 1991 (n ¼ 29) and 2 from 1992 to 2007 (n ¼ 24). No cases were excluded. In period 1 the immunosuppressive drugs used were Azathioprine and Prednisone, and in period 2 mainly Cyclosporine and Prednisone. Results of the two groups will be compared.
Results
There were no maternal deaths in either of the periods. There were three perinatal deaths, all before 1992. Three babies (13.8%) in period 1 and two (11.5%) in period 2 were delivered before 32 weeks and 15 (51.7%) vs 11 (42.3%) before 37 weeks. Fifteen newborns (51.7%) in period 1 and 11 (52.0%) in period 2 weighed less than 2500. There were more PROM cases in period 1, and more preeclampsia and IUGR in period 2. Evolution of creatinine during pregnancy looks similar in both periods but after three or more years the increase in creatinine values was bigger in period 2.
Conclusion
Perinatal results are better in the second period, but the increase found in creatinine levels is of concern on renal function in this period.
The timely management of a phaeochromocytoma in pregnancy: series of three cases 
Case report
We report three cases of phaeochromocytoma in pregnancy. Medical management was utilized for up to 16 weeks and surgical removal of the tumour was deferred in all cases until five to eight weeks postpartum. All cases had good maternal and fetal outcomes.
A 30-year-old woman presented with labile blood pressure (BP) at 24 weeks of gestation. Noradrenaline levels were elevated in the 24-hour urine samples to 4470 nmol/24 hour. Abdominal ultrasound demonstrated a 5.2 Â 5.7 cm mass. She was rehydrated with intravenous fluids and treated with phenoxybenzamine and propanolol. An elective caesarean section at 37.5 weeks, under continued alpha and beta-blockade, resulted in a normotensive baby girl. Adrenalectomy was performed five weeks postpartum.
A 38-year-old woman presented with labile BP at 19 weeks of gestation. Noradrenaline levels were elevated in the 24-hour urine samples to 1130 nmol/24 hour. A magnetic resonance image scan demonstrated a 14.7 Â 10 cm mass displacing the left kidney.
She was rehydrated with intravenous fluids and treated with phenoxybenzamine and propanolol. Caesarean section at 35 weeks was performed under intravenous alpha and betablockade. This resulted in a normotensive baby girl. Adrenalectomy was performed six weeks postpartum.
A 28-year-old woman was shown to have a right adrenal mass on routine obstetric ultrasound at 20 weeks of gestation. Noradrenaline levels were elevated in the 24-hour urine samples to 2286 nmol/ 24 hour. She was rehydrated with intravenous fluids. She was brought to our care at 37 weeks and remained on intravenous alpha-blockade until delivery a week later. Laparoscopic adrenalectomy was performed two months postpartum.
Points for discussion
(1) Pharmacological treatment of phaeochromocytoma in pregnancy;
(2) Optimal timing of phaeochromocytoma surgery in patients who were diagnosed pregnant.
